Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade
Reactivation of functionally-impaired anticancer T cells by programmed cell death protein 1 (PD-1) and programmed cell death receptor ligand-1 (PD-L1) –blocking antibodies shows prominent therapeutic benefit in advanced melanoma and patients with non–small cell lung cancer. However, current PD-L1–blocking antibodies lack intrinsic tumor selectivity. Therefore, efficacy may be reduced resulting from on-target and off-tumor binding to PD-L1– expressing normal cells. This may lead to indiscriminate activation of antigen-experienced T cells, including those implicated in autoimmune-related adverse events.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Iris Koopmans, Mark A.J.M. Hendriks, Robert J. van Ginkel, Douwe F. Samplonius, Edwin Bremer, Wijnand Helfrich Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Dermatology | Eye Cancers | Lung Cancer | Melanoma | Skin | Skin Cancer | Uveal Melanoma